UA127588C2 - Способи застосування та композиції, які містять дулаглутид - Google Patents
Способи застосування та композиції, які містять дулаглутид Download PDFInfo
- Publication number
- UA127588C2 UA127588C2 UAA202002355A UAA202002355A UA127588C2 UA 127588 C2 UA127588 C2 UA 127588C2 UA A202002355 A UAA202002355 A UA A202002355A UA A202002355 A UAA202002355 A UA A202002355A UA 127588 C2 UA127588 C2 UA 127588C2
- Authority
- UA
- Ukraine
- Prior art keywords
- dulaglutide
- dose
- subject
- weeks
- once
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589244P | 2017-11-21 | 2017-11-21 | |
| PCT/US2018/060716 WO2019103875A2 (en) | 2017-11-21 | 2018-11-13 | Methods of using and compositions containing dulaglutide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA127588C2 true UA127588C2 (uk) | 2023-10-25 |
Family
ID=64572530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA202002355A UA127588C2 (uk) | 2017-11-21 | 2018-11-13 | Способи застосування та композиції, які містять дулаглутид |
Country Status (21)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113613629A (zh) * | 2019-03-15 | 2021-11-05 | 伊莱利利公司 | 防腐的制剂 |
| US20230088005A1 (en) * | 2020-01-30 | 2023-03-23 | Eli Lilly And Company | Therapeutic uses of dulaglutide |
| JP2023525898A (ja) * | 2020-05-19 | 2023-06-19 | エフ. ホフマン-ラ ロシュ アーゲー | 非経口タンパク質溶液における可視粒子の形成を防止するためのキレート剤の使用 |
| AU2022298662B2 (en) | 2021-06-23 | 2025-06-05 | Eli Lilly And Company | An incretin analog for use in glycemic control and weight management |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1724284T1 (sl) | 2000-12-07 | 2009-12-31 | Lilly Co Eli | Glp-1 fuzijski proteini |
| ES2371072T3 (es) | 2003-06-12 | 2011-12-27 | Eli Lilly And Company | Proteínas de fusión análogas de glp-1. |
| JP2008525452A (ja) | 2004-12-22 | 2008-07-17 | イーライ リリー アンド カンパニー | Glp−1類似体融合蛋白質製剤 |
| KR20100020516A (ko) * | 2007-07-10 | 2010-02-22 | 일라이 릴리 앤드 캄파니 | Glp-1-fc 융합 단백질 제제 |
| AR100639A1 (es) * | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| WO2016168388A2 (en) * | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| US20200171129A1 (en) | 2017-06-01 | 2020-06-04 | Eli Lilly And Company | Therapeutic uses of dulaglutide |
-
2018
- 2018-11-13 MA MA050798A patent/MA50798A/fr unknown
- 2018-11-13 PH PH1/2020/550795A patent/PH12020550795A1/en unknown
- 2018-11-13 CR CR20200202A patent/CR20200202A/es unknown
- 2018-11-13 UA UAA202002355A patent/UA127588C2/uk unknown
- 2018-11-13 EP EP18812499.4A patent/EP3713593A2/en active Pending
- 2018-11-13 AU AU2018372709A patent/AU2018372709B2/en active Active
- 2018-11-13 MX MX2020005231A patent/MX2020005231A/es unknown
- 2018-11-13 CN CN201880075369.5A patent/CN111356472A/zh active Pending
- 2018-11-13 CN CN202510640885.XA patent/CN120478602A/zh active Pending
- 2018-11-13 SG SG11202003687RA patent/SG11202003687RA/en unknown
- 2018-11-13 IL IL274563A patent/IL274563B2/en unknown
- 2018-11-13 PE PE2020000547A patent/PE20200847A1/es unknown
- 2018-11-13 JP JP2020525974A patent/JP7221956B2/ja active Active
- 2018-11-13 KR KR1020207014456A patent/KR102589234B1/ko active Active
- 2018-11-13 KR KR1020227035115A patent/KR20220146656A/ko not_active Ceased
- 2018-11-13 BR BR112020007817-4A patent/BR112020007817A2/pt not_active Application Discontinuation
- 2018-11-13 US US16/763,269 patent/US11576950B2/en active Active
- 2018-11-13 WO PCT/US2018/060716 patent/WO2019103875A2/en not_active Ceased
- 2018-11-13 EA EA202090971A patent/EA202090971A1/ru unknown
-
2020
- 2020-05-12 CL CL2020001252A patent/CL2020001252A1/es unknown
- 2020-05-20 EC ECSENADI202026436A patent/ECSP20026436A/es unknown
- 2020-05-21 JO JOJO/P/2020/0126A patent/JOP20200126B1/ar active
- 2020-06-01 DO DO2020000104A patent/DOP2020000104A/es unknown
-
2022
- 2022-02-01 JP JP2022014339A patent/JP7818412B2/ja active Active
- 2022-05-18 AU AU2022203372A patent/AU2022203372B2/en active Active
-
2023
- 2023-01-04 US US18/149,982 patent/US20240189394A1/en active Pending
-
2024
- 2024-02-16 JP JP2024021637A patent/JP2024056908A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7818412B2 (ja) | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 | |
| US12220392B2 (en) | Combination composition | |
| JP2021535161A5 (cg-RX-API-DMAC7.html) | ||
| CN107496907A (zh) | 诱导ii型糖尿病患者体重减轻或/和防止ii型糖尿病患者体重增加的药物组合产品 | |
| JP2019501886A5 (cg-RX-API-DMAC7.html) | ||
| US20110218206A1 (en) | Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use | |
| CA3204344A1 (en) | Treatment of hemophilia with fitusiran | |
| WO2022120291A1 (en) | Treatment of hemophilia with fitusiran | |
| JP2026500140A (ja) | 血漿カリクレイン関連障害を処置するための抗血漿カリクレイン抗体投薬レジメン | |
| KR102870956B1 (ko) | 조현병의 치료를 위한 일로페리돈 | |
| RU2015117995A (ru) | Композиции и способы лечения эктодермальной дисплазии | |
| TW202525306A (zh) | 用非妥西蘭(fitusiran)治療a型血友病 | |
| CA3082625C (en) | Methods of using and compositions containing dulaglutide | |
| CN109562149A (zh) | C1酯酶抑制剂的药物制剂 | |
| EA041605B1 (ru) | Способы применения и композиции, содержащие дулаглутид | |
| WO2021255438A1 (en) | Combination of dexamethasone and a mineralocorticoid receptor antagonist for use in the treatment of acute respiratory distress syndrome | |
| Gras | Berotralstat. Plasma kallikrein (KLKB1) inhibitor, Treatment of hereditary angioedema attacks | |
| Audhya et al. | Agreement between improvements in patient global impression of change and other measures of improvement and attack resolution observed in a phase 2 trial with sebetralstat (KVD900) in patients with hereditary angioedema | |
| CA3035327C (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
| Baker | New Dosage Forms and Indications Approved by the FDANew Drug/Biologics License Applications Filed by ManufacturerSignificant Labeling Changes or “Dear Health Professional” Letters Related to Safety: New Drugs Approved by the FDA | |
| HK1248551B (en) | Iloperidone for the treatment of schizophrenia |